Edgewise Therapeutics Reports 6-Month Interim (ARCH) Study Results of EDG-5506 for Becker Muscular Dystrophy
Shots:
- The (ARCH) open-label study evaluates EDG-5506 in 12 adult males with BMD. Patients were given a 10mg dose for the first 2mos., followed by a 15mg dose for 4mos.
- The result showed a positive trend in NSAD scores relative to BMD natural history trajectories, 8 of 12 patients showed functional improvement or exhibited no decline in NSAA, reduction in levels of serum CK & fast skeletal muscle troponin I (TNNI2) of 39% & 75%, plasma PK levels reached target exposures
- Reduction in key biomarkers of muscle damage, was well-tolerated at higher doses with no discontinuations or dose reductions, reducing contraction-induced injury in dystrophic muscle will retain & improve muscular function while avoiding disease development in dystrophinopathies
Ref: Buisnesswire | Image: Edgewise Therapeutics
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
